Genomic Advances in Heart Failure

Life Sciences, Drug Discovery & Development, Preclinical,
  • Tuesday, February 23, 2021

Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for those with reduced injection fraction (HFrEF). HFpEF has been called the greatest unmet need in cardiovascular disease given the number of heart failure deaths per year and the proportion of patients with HFpEF. Despite significant research into the drivers of heart failure, many patients remain undiagnosed or poorly managed and new therapies are needed.

This webinar will cover recent advances in heart failure genomics with a focus on translating findings into improved therapeutics and diagnosis. Genuity Science and their colleagues are building large-scale real-world datasets combining whole-genome sequencing and detailed longitudinal clinical data from thousands of participants. For heart failure, these datasets help scientists discover and validate new drug targets for heart failure and are enriched with participants with HFpEF. Additionally, the speakers will discuss what is currently known about genomic drivers of heart failure and opportunities for novel therapeutics being explored in their own research programs.

Register for this webinar to learn about recent advances in the genomics of heart failure.

Speakers

http://Benoit%20Tyl,%20Servier

Benoit Tyl, MD, FESC, Medical and Scientific Director, Cardiology, Servier

Dr. Benoit Tyl is the scientific and medical director of cardiology at Servier (France). He is a cardiologist with a strong experience as a clinician and a fellow of the European Society of Cardiology. He worked for the pharmaceutical industry R&D since more than 15 years in various companies as well as in various positions. Within Servier, he worked in the past years on several cardiovascular R&D projects related to ischemic cardiomyopathies, arrhythmia and Heart Failure. He served 5 years as director of translational cardiovascular R&D within the company. In this position he supported Servier’s Cardiovascular projects from basic science to the marketing authorization, mainly on Heart Failure. One of his main focus is to help fill the gap between the idea (target) and the drug, especially with regards to target validation, population selection, preclinical and clinical studies using various methods and techniques including biomarkers. He is working closely with researchers, developers, but also various specialists within Servier and outside. The improvement in clinical trials, particularily within cardiology is one of his other topics of interest. He is also leading for Servier several international public-private international efforts contributing to drug development including the IMI [email protected]

Message Presenter
http://Irene%20Blat,%20Genuity%20Science

Irene Blat, PhD, Senior Director of Data Products and Analytics, Genuity Science

Irene Blat leads the product and analytics strategy for Genuity Science cohorts, platform and sequencing businesses. She brings 15 years of experience in genomics across academia, industry and IP law. Irene began her career at the Broad Institute where she helped launch the Connectivity Map, a database triangulating the link between gene perturbation, disease and function.

During her graduate studies at the Koch Institute of Integrative Cancer Research at MIT, Irene investigated the role of genetic modifiers in the progression of lung and colorectal tumors. Her work led to the identification of the timing and spatial distribution of important genes in early and mature intestinal stem cell differentiation. She has since held a research role at Massachusetts General Hospital and later served as a Technology Specialist at the IP law firm Clark & Elbing. Irene holds a BS in Biology from Duke University and a PhD in Genetics from MIT.

Message Presenter
http://Ellen%20Gordon,%20PhD,%20Genuity%20Science

(Host) Ellen Gordon, PhD, Vice President, Business Development, Genuity Science

Ellen Gordon joined the commercial team at Genuity Science in 2020 with responsibility for cohort program sales and business development across several key pharmaceutical accounts.  Ellen has over 20 years of experience in healthcare and pharmaceutical research. Prior to joining Genuity Science, Ellen was responsible for sales and client solutions at GNS Healthcare, a leading provider of analytic solutions to pharmaceutical and health plan customers. Prior to that, she held senior positions at national and international market research firms where she gained an extensive background in designing and executing strategic custom research solutions globally.

Ellen holds a B.A. in Politics from Brandeis University, an M.A. in Russian Studies from Georgetown University and a Ph.D. in Political Science from the University of Michigan.

Message Presenter

Who Should Attend?

Industry: Pharma, Biotech

Job titles include:

  • Chief Scientific Officer
  • Head, Translational Medicine
  • Director Translational Biology
  • VP Translational Biology
  • R&D Dir., Platform
  • Senior or Principal Researcher
  • Senior or Principal Investigator
  • Senior or Principal Scientist
  • Head of Discovery Sciences
  • Senior Director, Early Development and Translational Sciences
  • Executive Vice President, Research and Development
  • Business Development
  • Business Development Manager

What You Will Learn

In this webinar, participants will learn about:

  • Recent advances in heart failure genomics
  • Improved diagnostic techniques and therapies
  • Findings from whole-genome sequencing data and clinical data

Xtalks Partner

Genuity Science

Genuity Science is a data sourcing, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP-accredited, CLIA-certified genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. Learn more at www.genuitysci.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account